CHST2: A Potential Drug Target Or Biomarker for Diabetes and Neurodegenerative Disorders

Target Name: CHST2

NCBI ID: G9435

CHST2

CHST2: A Potential Drug Target Or Biomarker for Diabetes and Neurodegenerative Disorders

CHST2 (GlcNAc6ST-1) is a protein that is expressed in various tissues of the human body, including the brain, heart, and kidneys. It is a key regulator of the transport of glucose into the cells, and is also involved in the regulation of inflammation and cellular signaling.

In recent years, research has suggested that CHST2 may be a drug target or biomarker for various diseases, including diabetes, heart disease, and neurodegenerative disorders. This is because CHST2 has been shown to play a role in the regulation of cellular processes that are involved in the development and progression of these diseases.

One of the key mechanisms by which CHST2 is involved in the regulation of glucose transport is through its role as a regulator of the GLUT1 protein. GLUT1 is a transmembrane protein that is involved in the uptake of glucose into the cells. CHST2 has been shown to interact with GLUT1 and regulate its activity. This interaction between CHST2 and GLUT1 suggests that CHST2 may be a potential drug target for diabetes.

In addition to its role as a regulator of GLUT1 activity, CHST2 has also been shown to be involved in the regulation of cellular signaling pathways that are involved in the development and progression of neurodegenerative disorders. For example, CHST2 has been shown to be involved in the regulation of the production of reactive oxygen species (ROS), which are highly reactive molecules that can cause damage to cells and contribute to the development of neurodegenerative disorders.

CHST2's involvement in the regulation of cellular signaling pathways also suggests that it may be a potential biomarker for neurodegenerative disorders. For example, the levels of CHST2 have been shown to be decreased in the brains of individuals with Alzheimer's disease, a neurodegenerative disorder. This suggests that CHST2 may be a potential drug target or biomarker for this disorder.

In conclusion, CHST2 (GlcNAc6ST-1) is a protein that is involved in the regulation of various cellular processes that are involved in the development and progression of diseases. Its role as a regulator of GLUT1 activity and its involvement in the regulation of cellular signaling pathways suggest that it may be a potential drug target or biomarker for a variety of diseases, including diabetes, heart disease, and neurodegenerative disorders. Further research is needed to fully understand the role of CHST2 in these processes and to develop effective treatments for these diseases.

Protein Name: Carbohydrate Sulfotransferase 2

Functions: Sulfotransferase that utilizes 3'-phospho-5'-adenylyl sulfate (PAPS) as sulfonate donor to catalyze the transfer of sulfate to position 6 of non-reducing N-acetylglucosamine (GlcNAc) residues within keratan-like structures on N-linked glycans and within mucin-associated glycans that can ultimately serve as SELL ligands. SELL ligands are present in high endothelial cells (HEVs) and play a central role in lymphocyte homing at sites of inflammation. Participates in biosynthesis of the SELL ligand sialyl 6-sulfo Lewis X and in lymphocyte homing to Peyer patches. Has no activity toward O-linked sugars. Its substrate specificity may be influenced by its subcellular location. Sulfates GlcNAc residues at terminal, non-reducing ends of oligosaccharide chains

The "CHST2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CHST2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets